Inspire Veterinary Partners filings document the public-company record for a Nevada issuer operating in U.S. veterinary and pet health care services. The record includes Form 8-K reports on exchange-listing status, material agreements, amendments to authorized Class A common stock, board changes, and other corporate governance matters.
Registration statements describe securities offerings and issuer classifications, while late-filing notices and Form 15 documentation address periodic reporting status under the Securities Exchange Act. The filings also cover Class A common stock, capital-structure changes, OTCQB trading following Nasdaq delisting, and the company’s formal suspension or termination of Exchange Act reporting duties.
Inspire Veterinary Partners, Inc. will hold its 2025 Annual Meeting on December 10, 2025 at 10 a.m. ET as a virtual audio webcast. Stockholders will vote to elect seven directors and to ratify M&K CPAS, PLLC as the independent auditor for 2025. The Board recommends voting FOR all nominees and FOR auditor ratification.
The record date is October 14, 2025. As of that date, 3,647,610 Class A shares were outstanding (one vote per share) and 3,020,750 Class B shares were outstanding (25 votes per share), giving Class B holders 75,518,750 votes. A quorum requires at least 26,441,565 votes represented in person or by proxy.
On October 16, 2025, the company appointed M&K CPAS, PLLC and dismissed Kreit & Chiu CPA LLP. There were no disagreements reported; K&C previously identified material weaknesses in internal control, and its 2023–2024 audit reports included an explanatory paragraph on substantial doubt about going concern.
Inspire Veterinary Partners (IVP) changed auditors. On October 16, 2025, the company dismissed Kreit & Chiu CPA LLP and appointed M&K CPAS, PLLC as its independent registered public accounting firm to audit the financial statements for the year ended December 31, 2025. The Audit Committee approved the change.
The company reported no disagreements with Kreit & Chiu on accounting principles, disclosure, or audit procedures. Kreit & Chiu previously identified material weaknesses in internal control over financial reporting, and its audit reports for 2024 and 2023 included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern. A letter from Kreit & Chiu dated October 21, 2025 is filed as Exhibit 16.1.
Inspire Veterinary Partners, Inc. (IVP) is filing an S-1 that describes a roll-up veterinary business model driven by acquisitions of individual hospitals and related real estate. For the six months ended June 30, 2025, the company reported $16.59M of revenue (flat year-over-year) and a net loss of $5.45M, and it sustained a net loss of $3.03M for the three months ended June 30, 2025. Management discloses substantial acquisitions completed since 2021 (multiple clinics with transaction values reported) and ongoing financing from notes, convertible instruments, a common stock purchase agreement and other debt.
The filing discloses notes payable of approximately $11.98M, elevated interest expense and non-cash charges that contributed to a going-concern statement: management says additional financing is required to continue operations for the next 12 months. The prospectus also notes a Nasdaq listing deficiency and potential dilution from a range of outstanding warrants, options and preferred conversions totaling material share counts.
Erinn Thomas-Mackey, a director of Inspire Veterinary Partners, Inc. (IVP), reported acquiring 1,447 shares of Class A common stock through the exercise of a stock option on 09/26/2024. The option had a listed exercise price of $17 and the transaction leaves Ms. Thomas-Mackey with 1,447 shares held directly. The Form 4 notes the reported share amounts were adjusted for a 25-for-1 reverse stock split effected by the issuer on 01/27/2025.
The filing also discloses that this Form 4 was submitted late due to an inadvertent administrative error and bears a signature date of 09/22/2025.
Erinn Thomas-Mackey, a director of Inspire Veterinary Partners, Inc. (IVP), reported acquiring 1,447 shares of Class A common stock through the exercise of a stock option on 09/26/2024. The option had a listed exercise price of $17 and the transaction leaves Ms. Thomas-Mackey with 1,447 shares held directly. The Form 4 notes the reported share amounts were adjusted for a 25-for-1 reverse stock split effected by the issuer on 01/27/2025.
The filing also discloses that this Form 4 was submitted late due to an inadvertent administrative error and bears a signature date of 09/22/2025.
Inspire Veterinary Partners, Inc. (IVP) filed an S-1 registration statement describing an offering of Class A common stock and related resale registration rights with investor Seven Knots, LLC. The company discloses it has a limited operating history, is not profitable, and has generated U.S. net operating loss carryforwards that may be unusable if future taxable income does not materialize. IVP lists numerous operational and regulatory risks including challenges integrating acquisitions, recruiting and retaining veterinarians, cybersecurity and data risks, compliance with state and federal veterinary and controlled-substance laws, and Nasdaq listing deficiency notices. The prospectus summarizes outstanding and potentially issuable equity: 3,609,285 Class A shares outstanding as of September 16, 2025; multiple tranches of warrants, options and convertible preferred stock that together could materially increase diluted shares (examples include 7,593,000 shares from conversion of Series B preferred, 1,092,896+1,092,896 warrants at $1.83, and 9,450,000 shares reserved under the 2022 Equity Incentive Plan). The offering contemplates up to 35,000,000 Class A shares in this offering on a pro forma as-adjusted basis and describes conditions required for purchase agreement effectiveness.
Inspire Veterinary Partners, Inc. (IVP) filed an S-1 registration statement describing an offering of Class A common stock and related resale registration rights with investor Seven Knots, LLC. The company discloses it has a limited operating history, is not profitable, and has generated U.S. net operating loss carryforwards that may be unusable if future taxable income does not materialize. IVP lists numerous operational and regulatory risks including challenges integrating acquisitions, recruiting and retaining veterinarians, cybersecurity and data risks, compliance with state and federal veterinary and controlled-substance laws, and Nasdaq listing deficiency notices. The prospectus summarizes outstanding and potentially issuable equity: 3,609,285 Class A shares outstanding as of September 16, 2025; multiple tranches of warrants, options and convertible preferred stock that together could materially increase diluted shares (examples include 7,593,000 shares from conversion of Series B preferred, 1,092,896+1,092,896 warrants at $1.83, and 9,450,000 shares reserved under the 2022 Equity Incentive Plan). The offering contemplates up to 35,000,000 Class A shares in this offering on a pro forma as-adjusted basis and describes conditions required for purchase agreement effectiveness.
Inspire Veterinary Partners, Inc. (IVP) director Phillip Balatsos submitted an initial Form 3 stating he does not beneficially own any securities of the issuer. The filing notes the Form 3 was submitted late due to an inadvertent administrative error. The disclosure lists the relevant event date as 10/09/2024 and indicates the form was filed by a single reporting person.
Inspire Veterinary Partners, Inc. reports that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), known as the stockholders’ equity requirement. Nasdaq notified the company on August 26, 2025 that, based on a filing made with the SEC on August 20, 2025, the company now meets the required level of stockholders’ equity for continued listing on the Nasdaq Capital Market. The company later issued a press release on September 2, 2025 to publicly announce that it is once again in compliance with this Nasdaq listing standard.
Inspire Veterinary Partners, Inc. reports that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), known as the stockholders’ equity requirement. Nasdaq notified the company on August 26, 2025 that, based on a filing made with the SEC on August 20, 2025, the company now meets the required level of stockholders’ equity for continued listing on the Nasdaq Capital Market. The company later issued a press release on September 2, 2025 to publicly announce that it is once again in compliance with this Nasdaq listing standard.
Alexandra Quarti, identified as Vice President of Medical Operations, filed an initial Form 3 reporting her relationship to Inspire Veterinary Partners, Inc. (IVP) and the event date of 08/20/2025. The form states she does not beneficially own any securities of the issuer. The filing lists her business address in Virginia Beach, VA, and confirms this is an individual filing by one reporting person.
Laura Elizabeth Johnson, Vice President of Operations and a director-level reporting person for Inspire Veterinary Partners, Inc. (IVP), filed an initial Form 3 reporting the event dated 08/20/2025. The filing lists the reporting persons name and business address and explicitly states no securities are beneficially owned. The form is signed and dated 08/22/2025.
Inspire Veterinary Partners, Inc. reported that Nasdaq previously notified the company on April 10, 2025 that its stockholders’ equity of $1,562,005 as of December 31, 2024 did not meet the Nasdaq Capital Market minimum under Listing Rule 5550(b)(1). The company submitted a compliance plan within the required 45-day window.
The company then entered into a Securities Purchase Agreement on July 28, 2025 for a private placement of up to 7,590 shares of Series B convertible preferred stock and accompanying warrants, with an aggregate offering amount of up to $10 million, to be sold in one or more closings. On July 29, 2025, it completed the first closing, issuing 6,340 shares of Series B Preferred Stock and 6,340,000 warrants for aggregate proceeds of approximately $5 million, received in cash and in securities in lieu of cash.
As of this report, the company believes that, because of the first closing of the private placement, it has regained compliance with Nasdaq’s stockholders’ equity requirement. Nasdaq will continue to monitor compliance, and the company may be subject to delisting if a future periodic report does not show that it remains in compliance.